Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Need for additional training to be a laboratory genetic counselor—A qualitative exploration
Schwartz, Lisa , Mackall, Mia S. , Arjunan, Aishwarya , Goodenberger, McKinsey L. , Mills, Rachel , Witherington, Sarah , Goodenberger, McKinsey , Arjunan, Aishwarya , Witherington, Sarah , Mills, Rachel

Mayo Clinic

Journal of Genetic Counseling | July 26, 2023 | Volume: 32 | Issue: 6 | Pages: 1249-1265

10.1002/jgc4.1746 | PMID 37493003 Get It

AbstractOpportunities for genetic counselors to work in the laboratory have grown exponentially, yet the professional development needed to serve in these roles had not been previously explored. This study aimed to identify competencies required for entry‐level genetic counselors working in the laboratory, explore the perceived level of preparation of these competencies as noted by experts in the laboratories, and assess the perceived value of additional credentialing for genetic counselors practicing in these settings. Twenty genetic counselors working in the laboratory setting and five MD or PhD laboratory managers, identified through purposeful and snowball sampling and with at least 5 years of experience working in a laboratory, were interviewed using a semi‐structured protocol. Transcripts were analyzed thematically using deductive and inductive coding. Key findings included the distinction of laboratory and industry roles as involving nondirect patient care and differing from genetic counseling roles in the clinical setting. Genetic counselors working in the laboratory feel well prepared to transition into this setting and provide a unique patient‐focused perspective to laboratory roles, including variant interpretation, marketing, and product development. Practice‐based competencies (PBCs) were translatable to those used in the laboratory, yet variant interpretation, limitations of genomics‐based tests, and the business of health care were noted as important to these roles but not fully addressed in the PBCs. Additional skills were often developed through on‐the‐job training and interdisciplinary collaboration, but more exposure to diverse roles in genetic counseling programs' didactic and field training was recommended. The majority felt that requiring an additional post‐master's credential to work in the laboratory setting may restrict movement into these roles. Several questioned their identity as genetic counselors as they were no longer providing direct patient care and/or had been dissuaded by others from pursuing a laboratory position. Research focused on professional identity among genetic counselors working in nondirect patient care roles is warranted.
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Paiva, Bruno , Manrique, Irene , Campbell, Timothy , Kazanecki, Christian C. , Martin, Nathan , Anderson, Larry D. , Berdeja, Jesús G. , Lonial, Sagar , Raje, Noopur , Munshi, Nikhil C. , Kaiser, Shari M. , Rytlewski, Julie , Campbell, Timothy , Kazanecki, Christian C , Martin, Nathan , Anderson, Larry D , Berdeja, Jesús G , Lonial, Sagar , Raje, Noopur S , Lin, Yi , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C , Kaiser, Shari M , Paiva, Bruno , Lin, Yi , Moreau, Philippe , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | July 24, 2023 | Volume: 4 | Issue: 5 | Pages: 365-373

10.1158/2643-3230.bcd-23-0044 | PMID 37486974 Get It

Abstract The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10−6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality. Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337
Patterns of pharmacotherapy for bipolar disorder: A GBC survey
Singh, Balwinder , Yocum, Anastasia K. , Strawbridge, Rebecca , Burdick, Katherine E. , Millett, Caitlin E. , Peters, Amy T. , Sperry, Sarah H. , Fico, Giovanna , Vieta, Eduard , Godin, Ophélia , McInnis, Melvin G. , Nierenberg, Andrew A. , Young, Allan H. , Berk, Michael , Williams, Lana J., Keramatian, Kamyar , Yatham, Lakshmi N. , Overs, Bronwyn J. , Roberts, Gloria , Zandi, Peter P. , Pham, Dániel , Frye, Mark A. , Collaborative, The FACE‐BD Collaborators, The Global Bipolar Cohort, Samalin, Ludovic , Godin, Ophelia , Leboyer, Marion , Etain, B , Tso, Ivy F , Coombes, Brandon J , Williams, Lana J , Keramatian, Kamyar , Fullerton, Janice M , Andreazza, Ana C , Zandi, Peter P , Biernacka, Joanna , Vieta, E , Singh, Balwinder , Pham, Daniel , Yatham, Lakshmi N , Young, Allan H , Strawbridge, Rebecca , Berk, Michael , Fico, Giovanna , McInnis, Melvin G , Millett, Caitlin E , Sperry, Sarah , Burdick, K E , Samalin, Ludovic , Verdolini, Norma , Leboyer, Marion , Étain, Bruno , Coombes, Brandon J. , Ashton, Melanie M. , Fullerton, Janice M. , Mitchell, Philip B , Andreassen, Ole A. , Andreazza, Ana C. , Biernacka, Joanna M. , Collaborative, The FACE‐BD Collaborators, The Global Bipolar Cohort

Mayo Clinic

Bipolar Disorders | July 18, 2023 | Volume: 26 | Issue: 1 | Pages: 22-32

10.1111/bdi.13366 | PMID 37463846 Get It

Abstract Objectives To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well‐characterized individuals with BD in North America, Europe, and Australia. Methods Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta‐analyses with generalized linear mixed methods were conducted to identify prescription patterns. Results This study included 10,351 individuals from North America ( n = 3985), Europe ( n = 3822), and Australia ( n = 2544). Overall, participants were predominantly female (60%) with BD‐I (60%; vs. BD‐II = 33%). Cross‐sectionally, mood‐stabilizing anticonvulsants (44%), second‐generation antipsychotics (42%), and antidepressants (38%) were the most prescribed medications. Lithium was prescribed in 29% of patients, primarily in the Australian (31%) and European (36%) cohorts. First‐generation antipsychotics were prescribed in 24% of the European versus 1% in the North American cohort. Antidepressant prescription rates were higher in BD‐II (47%) compared to BD‐I (35%). Major limitations were significant differences among cohorts based on inclusion/exclusion criteria, data source, and time/year of enrollment into cohort. Conclusions Mood‐stabilizing anticonvulsants, second‐generation antipsychotics, and antidepressants were the most prescribed medications suggesting prescription patterns that are not necessarily guideline concordant. Significant differences exist in the prescription practices across different geographic regions, especially the underutilization of lithium in the North American cohorts and the higher utilization of first‐generation antipsychotics in the European cohorts. There is a need to conduct future longitudinal studies to further explore these differences and their impact on outcomes, and to inform and implement evidence‐based guidelines to help improve treatment practices in BD.
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Yerushalmi, Rinat , Yablonski‐Peretz, Tamar, Wang, Qin , Bolla, Manjeet K. , Michailidou, Kyriaki , Ahearn, Thomas U. , Andrulis, Irene L. , Antoniou, Antonis C. , Auvinen, Päivi , Freeman, Laura Beane, Beckmann, Matthias W. , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Bojesen, Stig E. , Byers, Helen, Camp, Nicola J. , Chang‐Claude, Jenny , Chirlaque, María‐Dolores , Collaborators, NBCS, Collée, Margriet J., Dörk, Thilo , Eccles, Diana , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Goldberg, Mark S. , Guénel, Pascal , Hamann, Ute, He, Wei , Hillemanns, Peter , Hoppe, Reiner , Hopper, John L. , Investigators, ABCTB, Jakovchevska, Simona, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lejbkowicz, Flavio, Lindblom, Annika , Loibl, Sibylle , Lori, Adriana , Mannermaa, Arto, Manoochehri, Mehdi, Mavroudis, Dimitrios, Menon, Usha , Nevelsteen, Ines, Obi, Nadia , Offit, Ken, Plaseska‐Karanfilska, Dijana , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Schwentner, Lukas , Shah, Mitul , Stone, Jennifer , Taylor, Jack A. , Kolk, Lizet E. van der, Wendt, Camilla, Yang, Xiaohong R. , Zheng, Wei , Pharoah, Paul D.P. , Easton, Douglas F. , Ben-Sachar, Shay, Elefant, Naama , Shamir, Ron , Elkon, Ran , Lambrechts, Diether , Michailidou, Kyriaki , Antoniou, Antonis C , Devilee, Peter , Eccles, Diana , Newman, William G , Radice, Paolo , Elkon, Ran , Dörk, Thilo , Lambrechts, Diether , Hillemanns, Peter , Pharoah, Paul D P , Menon, Usha , Evans, D Gareth , John, Esther M , Jones, Michael E , Lambrechts, Diether , Guénel, Pascal , Romero, Atocha , García-Closas, Montserrat , Bogdanova, Natalia V , Taylor, Jack A , Zheng, Wei , Kurian, Allison W , Stone, Jennifer , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Levi, Hagai , Carmi, Shai , Rosset, Saharon , Zick, Aviad , Dennis, Joe , Lush, Michael J. , Anton‐Culver, Hoda , Arndt, Volker , Augustinsson, Annelie , Behrens, Sabine , Brenner, Hermann , Castelao, Jose E. , Chung, Wendy K. , Clarke, Christine L. , Collaborators, NBCS, Collée, Margriet , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Devilee, Peter , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Giles, Graham G. , Hall, Per N , Hollestelle, Antoinette , Investigators, ABCTB, Jakubowska, Anna , Jernström, Helena , Vijai, Joseph , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Mannermaa, Arto, Mulligan, Anna Marie , Murphy, Rachel A. , Newman, William G. , O’Brien, Katie M. , Olshan, Andrew F. , Olson, Janet E. , Panico, Salvatore , Peterlongo, Paolo , Radice, Paolo , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Sharma, Priyanka , Simard, Jacques , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Toland, Amanda Ewart , Troester, Melissa A. , Truong, Thérèse , Weinberg, Clarice R. , Ziogas, Argyrios , Dunning, Alison M.

Mayo Clinic

Journal of Medical Genetics | July 14, 2023 | Volume: 60 | Issue: 12 | Pages: 1186-1197

10.1136/jmg-2023-109185 | PMID 37451831 Get It

Background Polygenic risk score (PRS), calculated based on genome-wide association studies (GWASs), can improve breast cancer (BC) risk assessment. To date, most BC GWASs have been performed in individuals of European (EUR) ancestry, and the generalisation of EUR-based PRS to other populations is a major challenge. In this study, we examined the performance of EUR-based BC PRS models in Ashkenazi Jewish (AJ) women. Methods We generated PRSs based on data on EUR women from the Breast Cancer Association Consortium (BCAC). We tested the performance of the PRSs in a cohort of 2161 AJ women from Israel (1437 cases and 724 controls) from BCAC (BCAC cohort from Israel (BCAC-IL)). In addition, we tested the performance of these EUR-based BC PRSs, as well as the established 313-SNP EUR BC PRS, in an independent cohort of 181 AJ women from Hadassah Medical Center (HMC) in Israel. Results In the BCAC-IL cohort, the highest OR per 1 SD was 1.56 (±0.09). The OR for AJ women at the top 10% of the PRS distribution compared with the middle quintile was 2.10 (±0.24). In the HMC cohort, the OR per 1 SD of the EUR-based PRS that performed best in the BCAC-IL cohort was 1.58±0.27. The OR per 1 SD of the commonly used 313-SNP BC PRS was 1.64 (±0.28). Conclusions Extant EUR GWAS data can be used for generating PRSs that identify AJ women with markedly elevated risk of BC and therefore hold promise for improving BC risk assessment in AJ women.
Modest Effects of Osteoclast‐Specific ERα Deletion after Skeletal Maturity
Doolittle, Madison L. , Eckhardt, Brittany, Vos, Stephanie J. B. , Grain, Sarah, Rowsey, Jennifer L. , Ruan, Ming, Saul, Dominik , Farr, Joshua N. , Weivoda, Megan , Khosla, Sundeep , Eckhardt, Brittany A, Vos, Stephanie J, Weivoda, Megan M, Monroe, David G , Khosla, Sundeep , Farr, Joshua N , Saul, Dominik , Vos, Stephanie J., Monroe, David G.

Mayo Clinic

JBMR Plus | July 13, 2023 | Volume: 7 | Issue: 10 | Pages: No page available

10.1002/jbm4.10797 | PMID 37808391 Get It

ABSTRACT Estrogen regulates bone mass in women and men, but the underlying cellular mechanisms of estrogen action on bone remain unclear. Although both estrogen receptor (ER)α and ERβ are expressed in bone cells, ERα is the dominant receptor for skeletal estrogen action. Previous studies using either global or cell‐specific ERα deletion provided important insights, but each of these approaches had limitations. Specifically, either high circulating sex steroid levels in global ERα knockout mice or the effects of deletion of ERα during growth and development in constitutive cell‐specific knockout mice have made it difficult to clearly define the role of ERα in specific cell types in the adult skeleton. We recently generated and characterized mice with tamoxifen‐inducible ERα deletion in osteocytes driven by the 8‐kb Dmp1 promoter (ERαΔOcy mice), revealing detrimental effects of osteocyte‐specific ERα deletion on trabecular bone volume (−20.1%) and bone formation rate (−18.9%) in female, but not male, mice. Here, we developed and characterized analogous mice with inducible ERα deletion in osteoclasts using the Cathepsin K promoter (ERαΔOcl mice). In a study design identical to that with the previously described ERαΔOcy mice, adult female, but not male, ERαΔOcl mice showed a borderline (−10.2%, p = 0.084) reduction in trabecular bone volume, no change in osteoclast numbers, but a significant increase in serum CTx levels, consistent with increased osteoclast activity. These findings in ERαΔOcl mice differ from previous studies of constitutive osteoclast‐specific ERα deletion, which led to clear deficits in trabecular bone and increased osteoclast numbers. Collectively, these data indicate that in adult mice, estrogen action in the osteocyte is likely more important than via the osteoclast and that ERα deletion in osteoclasts from conception onward has more dramatic skeletal effects than inducible osteoclastic ERα deletion in adult mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (trial in progress)
Grischke, E.‐M., O’Sullivan, Ciara C. , Tryfonidis, Konstantinos, Santarpia, Libero, Yang, Shan, Hamilton, Erika , Martín, Miguel , Sohn, Joohyuk , Dièras, Véronique

Mayo Clinic

Senologie - Zeitschrift für Mammadiagnostik und -therapie | July 12, 2023 | Volume: 20 | Issue: 02 | Pages: e4-e5

10.1055/s-0043-1769138 Get It

Feasibility and Clinical Utility of Prediction Models for Breast Cancer–Related Lymphedema Incorporating Racial Differences in Disease Incidence
Rochlin, Danielle H. , Barrio, Andrea V. , McLaughlin, Sarah A. , Woods, Jack , Coriddi, Michelle , McGrath, Leslie, Bloomfield, E., Mehrara, Babak J. , Zee, Kimberly J. Van , Dayan, Joseph H. , McGrath, Leslie, Bloomfield, Emily A., Boe, Lillian A.

Mayo Clinic

JAMA Surgery | July 12, 2023 | Volume: 158 | Issue: 9 | Pages: 954

10.1001/jamasurg.2023.2414 | PMID 37436762 Get It

ImportanceBreast cancer–related lymphedema (BCRL) is a common complication of axillary lymph node dissection (ALND) but can also develop after sentinel lymph node biopsy (SLNB). Several models have been developed to predict the risk of disease development before and after surgery; however, these models have shortcomings that include the omission of race, inclusion of variables that are not readily available to patients, low sensitivity or specificity, and lack of risk assessment for patients treated with SLNB.ObjectiveTo create simple and accurate prediction models for BCRL that can be used to estimate preoperative or postoperative risk.Design, Setting, and ParticipantsIn this prognostic study, women with breast cancer who underwent ALND or SLNB from 1999 to 2020 at Memorial Sloan Kettering Cancer Center and the Mayo Clinic were included. Data were analyzed from September to December 2022.Main Outcomes and MeasuresDiagnosis of lymphedema based on measurements. Two predictive models were formulated via logistic regression: a preoperative model (model 1) and a postoperative model (model 2). Model 1 was externally validated using a cohort of 34 438 patients with an International Classification of Diseases diagnosis of breast cancer.ResultsOf 1882 included patients, all were female, and the mean (SD) age was 55.6 (12.2) years; 80 patients (4.3%) were Asian, 190 (10.1%) were Black, 1558 (82.8%) were White, and 54 (2.9%) were another race (including American Indian and Alaska Native, other race, patient refused to disclose, or unknown). A total of 218 patients (11.6%) were diagnosed with BCRL at a mean (SD) follow-up of 3.9 (1.8) years. The BCRL rate was significantly higher among Black women (42 of 190 [22.1%]) compared with all other races (Asian, 10 of 80 [12.5%]; White, 158 of 1558 [10.1%]; other race, 8 of 54 [14.8%]; P < .001). Model 1 included age, weight, height, race, ALND/SLNB status, any radiation therapy, and any chemotherapy. Model 2 included age, weight, race, ALND/SLNB status, any chemotherapy, and patient-reported arm swelling. Accuracy was 73.0% for model 1 (sensitivity, 76.6%; specificity, 72.5%; area under the receiver operating characteristic curve [AUC], 0.78; 95% CI, 0.75-0.81) at a cutoff of 0.18, and accuracy was 81.1% for model 2 (sensitivity, 78.0%; specificity, 81.5%; AUC, 0.86; 95% CI, 0.83-0.88) at a cutoff of 0.10. Both models demonstrated high AUCs on external (model 1: 0.75; 95% CI, 0.74-0.76) or internal (model 2: 0.82; 95% CI, 0.79-0.85) validation.Conclusions and RelevanceIn this study, preoperative and postoperative prediction models for BCRL were highly accurate and clinically relevant tools comprised of accessible inputs and underscored the effects of racial differences on BCRL risk. The preoperative model identified high-risk patients who require close monitoring or preventative measures. The postoperative model can be used for screening of high-risk patients, thus decreasing the need for frequent clinic visits and arm volume measurements.
Bundled Care to Reduce Sepsis Mortality: The Improving Pediatric Sepsis Outcomes (IPSO) Collaborative
Paul, Raina, Niedner, Matthew , Riggs, Ruth , Richardson, Troy , Balamuth, Frances, Campbell, Deborah, Depinet, Holly, Hueschen, Leslie A. , Kandil, Sarah , Larsen, Gitte , Mack, Elizabeth H. , Priebe, Gregory P. , Rutman, Lori , Schafer, Melissa , Scott, Halden F. , Silver, Pete, Stalets, Erika , Wathen, Beth A., Macias, Charles G. , Brilli, Richard J., INVESTIGATORS, for the IPSO COLLABORATIVE, Souza, Heidi G. De , Auletta, Jeffery J. , Balamuth, Fran , Huskins, W. Charles , Silver, Pete, Wathen, Beth, INVESTIGATORS, for the IPSO COLLABORATIVE

Mayo Clinic

Pediatrics | July 12, 2023 | Volume: 152 | Issue: 2 | Pages: No page available

10.1542/peds.2022-059938 | PMID 37435672 Get It

OBJECTIVES We sought to improve utilization of a sepsis care bundle and decrease 3- and 30- day sepsis-attributable mortality, as well as determine which care elements of a sepsis bundle are associated with improved outcomes. METHODS Children’s Hospital Association formed a QI collaborative to Improve Pediatric Sepsis Outcomes (IPSO) (January 2017–March 2020 analyzed here). IPSO Suspected Sepsis (ISS) patients were those without organ dysfunction where the provider “intended to treat” sepsis. IPSO Critical Sepsis (ICS) patients approximated those with septic shock. Process (bundle adherence), outcome (mortality), and balancing measures were quantified over time using statistical process control. An original bundle (recognition method, fluid bolus < 20 min, antibiotics < 60 min) was retrospectively compared with varying bundle time-points, including a modified evidence-based care bundle, (recognition method, fluid bolus < 60 min, antibiotics < 180 min). We compared outcomes using Pearson χ-square and Kruskal Wallis tests and adjusted analysis. RESULTS Reported are 24 518 ISS and 12 821 ICS cases from 40 children’s hospitals (January 2017–March 2020). Modified bundle compliance demonstrated special cause variation (40.1% to 45.8% in ISS; 52.3% to 57.4% in ICS). The ISS cohort’s 30-day, sepsis-attributable mortality dropped from 1.4% to 0.9%, a 35.7% relative reduction over time (P < .001). In the ICS cohort, compliance with the original bundle was not associated with a decrease in 30-day sepsis-attributable mortality, whereas compliance with the modified bundle decreased mortality from 4.75% to 2.4% (P < .01). CONCLUSIONS Timely treatment of pediatric sepsis is associated with reduced mortality. A time-liberalized care bundle was associated with greater mortality reductions.
Factors Associated With Improved Pediatric Resuscitative Care in General Emergency Departments
Auerbach, Marc , Whitfill, Travis , Montgomery, Erin , Leung, James , Kessler, David , Gross, Isabel T. , Walsh, Barbara , Hamilton, Melinda, Gawel, Marcie, Kant, Shruti, Janofsky, Stephen , Brown, Linda , Walls, Theresa A. , Alletag, Michelle, Sessa, Anna , Arteaga, Grace M. , Keilman, Ashley , Ittersum, Wendy Van, Rutman, Maia S. , Zaveri, Pavan , Good, Grace , Schoen, Jessica C. , Lavoie, Meghan B., Mannenbach, Mark S., Bigham, Ladonna, Rutledge, Chrystal , Okada, Pamela J. , Moegling, Michelle , Anderson, Ingrid , Tay, Khoon‐Yen , Scherzer, Daniel , Vora, Samreen , Gaither, Stacy , Fenster, Daniel, Jones, Derick D. , Chatfield, Jenny, Knight, Lynda, Berg, Marc , Makharashvili, Ana, Katznelson, Jessica , Mathias, Emily, Lutfi, Riad , Abu‐Sultaneh, Samer , Padlipsky, Patricia, Lee, Jumie , Butler, Lucas, Alander, Sarah W., Bhatnagar, Ambika , Crellin, Jason, Mannenbach, Mark, Jones, Derick, Sessa, Anna, Lavoie, Meghan, Dudas, Robert Arthur , Aebersold, Michelle , Burns, Brian, Thomas, Anita Anne , Jafri, Farrukh Nadeem , Abulebda, Kamal

Mayo Clinic

Pediatrics | July 7, 2023 | Volume: 152 | Issue: 2 | Pages: No page available

10.1542/peds.2022-060790 | PMID 37416979 Get It

OBJECTIVES To describe the quality of pediatric resuscitative care in general emergency departments (GEDs) and to determine hospital-level factors associated with higher quality. METHODS Prospective observational study of resuscitative care provided to 3 in situ simulated patients (infant seizure, infant sepsis, and child cardiac arrest) by interprofessional GED teams. A composite quality score (CQS) was measured and the association of this score with modifiable and nonmodifiable hospital-level factors was explored. RESULTS A median CQS of 62.8 of 100 (interquartile range 50.5–71.1) was noted for 287 resuscitation teams from 175 emergency departments. In the unadjusted analyses, a higher score was associated with the modifiable factor of an affiliation with a pediatric academic medical center (PAMC) and the nonmodifiable factors of higher pediatric volume and location in the Northeast and Midwest. In the adjusted analyses, a higher CQS was associated with modifiable factors of an affiliation with a PAMC and the designation of both a nurse and physician pediatric emergency care coordinator, and nonmodifiable factors of higher pediatric volume and location in the Northeast and Midwest. A weak correlation was noted between quality and pediatric readiness scores. CONCLUSIONS A low quality of pediatric resuscitative care, measured using simulation, was noted across a cohort of GEDs. Hospital factors associated with higher quality included: an affiliation with a PAMC, designation of a pediatric emergency care coordinator, higher pediatric volume, and geographic location. A weak correlation was noted between quality and pediatric readiness scores.
Multifocal Extramedullary Plasma Cell Myeloma of the Colon
Karime, Christian , Sileno, Sean, Pisipati, Sailaja , Lam‐Himlin, Dora , Umar, Sarah B. , Sileno, Sean M, Lam-Himlin, Dora M

Mayo Clinic

ACG Case Reports Journal | July 6, 2023 | Volume: 10 | Issue: 7 | Pages: e01081

10.14309/crj.0000000000001081 | PMID 37426567 Get It